Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)
Head & Neck2020Vol. 42(10), pp. 2852–2862
Citations Over TimeTop 10% of 2020 papers
Chia‐Jui Yen, Naomi Kiyota, Nobuhiro Hanai, Shunji Takahashi, Tomoya Yokota, Shigemichi Iwae, Yasushi Shimizu, Ruey‐Long Hong, Masahiro Goto, Jin‐Hyoung Kang, Wing Sum Kenneth Li, Robert L. Ferris, Maura L. Gillison, Toshimitsu Endo, Vijayvel Jayaprakash, Makoto Tahara
Abstract
NCT02105636.
Related Papers
- → Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer(2018)886 cited
- → Severe infusion reaction due to nivolumab: A case report(2020)8 cited
- → A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma(2023)3 cited
- BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer(2018)
- → P2.04-39 Clinical Characteristics of Long-Term Survivors with Nivolumab in Previously Treated Advanced NSCLC from Real World Data(2019)